In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model
| Autor: | Jean-Pierre Bizzari, Alain Dhainaut, Nicolas Guilbaud, Maryse Berlion, Suzy Cros, Theresa A. Dunn, Ghanem Atassi, Gilbert Regnier |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Cancer Research
Vincristine Drug Evaluation Preclinical Drug Resistance Potential candidate Mice Inbred Strains Drug resistance Pharmacology Toxicology Drug Administration Schedule Mice Piperidines In vivo Antineoplastic Combined Chemotherapy Protocols medicine Animals Pharmacology (medical) Antitumor activity Dose-Response Relationship Drug Leukemia P388 Triazines business.industry Therapeutic effect medicine.disease Multiple drug resistance Leukemia Oncology Immunology Female business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 30:491-494 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/bf00685604 |
| Popis: | S 9788, a new triazinoaminopiperidine derivative, was found to be a potent reversant of vincristine resistance in the in vivo murine leukemic P388/VCR model. In two treatment regimens (Q4D days 1, 5 and 9 and QD days 1-9), S 9788 enhanced the antitumor activity of vincristine in a dose-dependent manner, resulting in a complete circumvention of drug resistance for well-tolerated doses of S 9788. S 9788 was also effective in enhancing therapeutic effects of vincristine in the treatment of sensitive P388-bearing mice. These results strongly suggest that S 9788 may be a potential candidate for circumvention of multidrug resistance (MDR) in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink